not FDA-approved as of June 2026
Common Symptoms: Incision pain, shoulder/abdominal gas pain, nausea, fatigue, light-headedness, temporary appetite loss, bloating, and emotional ups and downs
We commonly use BPC-157 as part of our treatment for the following conditions: Chronic gastrointestinal (GI) issues, including colitis, Crohns disease, irritable bowel disease (IBD), gastritis, ulcers, and esophagitis
Whether used alone or with compounded semaglutide or compound tirzepatide, this peptide promises to be a central figure in the future of obesity management and research
Generally, it'sconsidered to have a high safety profile in preclinical research with no acute toxicity observed, but potential downsides exist